Biophytis Reports First-Half 2025 Results and Provides Strategic Update
Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook.
Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half of 2025 marks a decisive milestone in the execution of our strategy. With the signing of a memorandum of understanding to create a joint venture in Asia, we are paving the way for the world’s first Phase 3 clinical trial in sarcopenia. At the same time, EMBRAPII’s support in Brazil for our Phase 2 obesity trial confirms the potential of BIO101 in combination with GLP-1 therapies. These tangible advances, together with the planned strengthening of our research platform, position Biophytis to sustainably improve the lives of millions of patients and create long-term value for our shareholders.”